DX&Vx Introduces Pharmaceuticals at Chinese Pediatric Society Conference

DXVX announced on the 30th that it participated in the "28th National Pediatric Academic Conference of the Chinese Medical Association" through its Chinese subsidiary, introducing its pharmaceuticals, including the azithromycin antibiotic, to Chinese pediatric specialists.

The conference, held from the 26th to the 29th at the Tianfu International Convention Center in Chengdu, Sichuan Province, China, is a national level Grade 1 event hosted by the Chinese Medical Association, the largest medical association in China. It is an international academic event attended by over 10,000 participants annually, including renowned pediatric specialists worldwide and Chinese pediatricians.

DxVx BJ (Beijing DIWEISI Biotechnology Co., Ltd.) participated in the conference to enhance external recognition and promoted azithromycin antibiotics, which are gaining attention as a treatment for pneumonia currently spreading in China. In addition, the company informed Chinese specialists about the types and efficacy of its pharmaceuticals, including arthritis supplements and skin disease treatments.

The azithromycin antibiotic supplied by DxVx BJ uses raw materials from PLIVA Croatia Ltd., the same as the original drug, through a member company of Sinopharm, the largest state-owned pharmaceutical group in China, ensuring the same quality and efficacy as the original azithromycin antibiotic.

Professor Eom Jung-sik from Gachon University College of Medicine's Department of Infectious Diseases, invited to the conference, presented on the topic "Azithromycin as the First Choice for Mycoplasma Infection," discussing the characteristics of mycoplasma pneumonia currently spreading in China and azithromycin antibiotics, known internationally as the top priority treatment.

As demand for azithromycin has recently increased, the differentiated raw materials, efficacy, and safety of DXVX BJ's antibiotics were introduced, attracting high interest from local medical professionals.

A DXVX official stated, "Our antibiotics are gaining attention as a treatment for mycoplasma pneumonia spreading recently in China, and the market demand is exceeding supply." He added, "We will do our best to contribute to preventing the spread of infectious diseases by expanding supply volumes."

Meanwhile, DXVX plans to use its branded antibiotics as a starting point for entering the Chinese healthcare market and intends to expand its portfolio with a larger lineup of basic pharmaceuticals, best-in-class products, and new drugs in the future.

This content was produced with the assistance of AI translation services.